Integrin β6 Inhibitors

Integrin β6 inhibitors constitute a diverse group of compounds that interact with the Integrin β6 subunit or its related pathways to inhibit its function. These inhibitors range from peptides that directly compete with natural ligands for binding to the integrin, such as RGD Peptide and Cyclo(RGDyK), to small molecules that modulate the interaction of integrins with the extracellular matrix, such as SB273005 and Cilengitide. Some inhibitors act indirectly by influencing other integrins or cell signaling pathways that can affect Integrin β6 function. For example, Tirofiban and Eptifibatide are known to affect platelet aggregation by targeting other integrins, which can indirectly impact Integrin β6 signaling. LAPTM4B, while not a chemical, is included as it can modulate Integrin β6 expression on the cell surface.

Other inhibitors act on cellular pathways that regulate integrin expression or stability. Deferoxamine disrupts iron homeostasis, thereby affecting the stability of HIF-1α, which can lead to altered integrin expression. NSC 74859 targets the STAT3 signaling pathway, known to regulate gene expression, including that of integrins, therefore decreasing Integrin β6 signaling. PD173074 and LDN-193189 inhibit growth factor signaling pathways, such as FGFR and BMP, respectively, which can lead to changes in integrin expression patterns and subsequent signaling. Lastly, Marimastat impacts Integrin β6 function by modifying the ECM through its MMP inhibitory activity, affecting the ligand availability for integrin binding and signaling.